Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387275 | 0.94 | GPR119 (0.66) | GPR119 | |
| SCHEMBL14191033 | 0.90 | GPR119 (0.66) | GPR119 | |
| SCHEMBL14191013 | 0.89 | GPR119 (0.65) | GPR119GPR183 | |
| SCHEMBL389015 | 0.89 | GPR119 (0.75) | GPR119 | |
| SCHEMBL387608 | 0.89 | GPR119 (0.63) | GPR119 | |
| SCHEMBL3983967 | 0.89 | GPR119 (0.58) | GPR119GPR183 | |
| SCHEMBL3980457 | 0.87 | GPR119 (0.61) | GPR119GPR183 | |
| SCHEMBL388632 | 0.87 | GPR119 (0.69) | GPR119GPR183 | |
| SCHEMBL869594 | 0.87 | GPR119 (0.60) | GPR119GPR183 | |
| SCHEMBL387364 | 0.87 | GPR119 (0.56) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | claimed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | claimed |
| JP-2010512334-A | — | — | 2010-04-22 | — | — | JP | claimed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | claimed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | claimed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | claimed |
| EP-2858986-B1 | PIPERIDINE DERIVATIVES AS GPR119 AGONISTS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-10-30 | — | — | EP | disclosed |
| US-9944600-B2 | Piperidine derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | US | disclosed |
| EP-2858986-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013187646-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-12-19 | — | — | WO | disclosed |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | GPR119 1/4885GPR183 1491/4885 |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | GPR119, FFAR2, GPR84 | GPR119 1/4885GPR183 32/4885 |
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | GPR119 1/4885GPR183 33/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | GPR119 1/4885GPR183 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.